BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

693 related articles for article (PubMed ID: 33778133)

  • 1. Immune evasion by cancer stem cells.
    Tsuchiya H; Shiota G
    Regen Ther; 2021 Jun; 17():20-33. PubMed ID: 33778133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NK cell-based therapeutics for lung cancer.
    Pockley AG; Vaupel P; Multhoff G
    Expert Opin Biol Ther; 2020 Jan; 20(1):23-33. PubMed ID: 31714156
    [No Abstract]   [Full Text] [Related]  

  • 3. Application of PD-1 Blockade in Cancer Immunotherapy.
    Wu X; Gu Z; Chen Y; Chen B; Chen W; Weng L; Liu X
    Comput Struct Biotechnol J; 2019; 17():661-674. PubMed ID: 31205619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.
    Chen X; Pan X; Zhang W; Guo H; Cheng S; He Q; Yang B; Ding L
    Acta Pharm Sin B; 2020 May; 10(5):723-733. PubMed ID: 32528824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging role of natural products in cancer immunotherapy.
    Dong S; Guo X; Han F; He Z; Wang Y
    Acta Pharm Sin B; 2022 Mar; 12(3):1163-1185. PubMed ID: 35530162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model.
    Zheng F; Dang J; Zhang H; Xu F; Ba D; Zhang B; Cheng F; Chang AE; Wicha MS; Li Q
    J Immunother; 2018 Oct; 41(8):361-368. PubMed ID: 30063587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
    Maccalli C; Parmiani G; Ferrone S
    Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in drug delivery systems for targeting cancer stem cells.
    Duan H; Liu Y; Gao Z; Huang W
    Acta Pharm Sin B; 2021 Jan; 11(1):55-70. PubMed ID: 33532180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma.
    Combe P; de Guillebon E; Thibault C; Granier C; Tartour E; Oudard S
    Oncoimmunology; 2015 May; 4(5):e1001236. PubMed ID: 26155388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harnessing stemness and PD-L1 expression by AT-rich interaction domain-containing protein 3B in colorectal cancer.
    Liao TT; Lin CC; Jiang JK; Yang SH; Teng HW; Yang MH
    Theranostics; 2020; 10(14):6095-6112. PubMed ID: 32483441
    [No Abstract]   [Full Text] [Related]  

  • 13. GITR agonist enhances vaccination responses in lung cancer.
    Zhu LX; Davoodi M; Srivastava MK; Kachroo P; Lee JM; St John M; Harris-White M; Huang M; Strieter RM; Dubinett S; Sharma S
    Oncoimmunology; 2015 Apr; 4(4):e992237. PubMed ID: 26137407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the immunogenicity of ALDH(high) human head and neck squamous cell carcinoma cancer stem cells in vitro.
    Prince MEP; Zhou L; Moyer JS; Tao H; Lu L; Owen J; Etigen M; Zheng F; Chang AE; Xia J; Wolf G; Wicha MS; Huang S; Ren X; Li Q
    Oral Oncol; 2016 Aug; 59():30-42. PubMed ID: 27424180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy.
    Draghiciu O; Lubbers J; Nijman HW; Daemen T
    Oncoimmunology; 2015 Jan; 4(1):e954829. PubMed ID: 25949858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer Stem Cells: Emerging Key Players in Immune Evasion of Cancers.
    Lei MML; Lee TKW
    Front Cell Dev Biol; 2021; 9():692940. PubMed ID: 34235155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.
    Kok VC
    Front Oncol; 2020; 10():268. PubMed ID: 32185135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene methylation in gastric cancer.
    Qu Y; Dang S; Hou P
    Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-34a regulates epithelial-mesenchymal transition and cancer stem cell phenotype of head and neck squamous cell carcinoma in vitro.
    Sun Z; Hu W; Xu J; Kaufmann AM; Albers AE
    Int J Oncol; 2015 Oct; 47(4):1339-50. PubMed ID: 26323460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.